Grifols Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Grifols şirketinin toplam hissedar öz sermayesi €8.3B ve toplam borcu €10.4B olup, bu da borç-öz sermaye oranını 125% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €22.3B ve €14.0B dir. Grifols 'in FAVÖK'ü €865.1M faiz karşılama oranı 1.8 dur. Şirketin €2.3B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

125.0%

Borç/özkaynak oranı

€10.37b

Borç

Faiz karşılama oranı	1.8x
Nakit	€2.26b
Eşitlik	€8.30b
Toplam yükümlülükler	€14.00b
Toplam varlıklar	€22.29b

Son finansal sağlık güncellemeleri

Recent updates

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Feb 20

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Jan 09

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Nov 10

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Is Grifols (BME:GRF) A Risky Investment?

Aug 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GRF 'nin kısa vadeli varlıkları ( €6.9B ) kısa vadeli yükümlülüklerini ( €4.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: GRF 'un kısa vadeli varlıkları ( €6.9B ) uzun vadeli yükümlülüklerini ( €9.9B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GRF 'nin net borç/öz sermaye oranı ( 97.8% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: GRF 'nin borç/öz sermaye oranı son 5 yılda 129% seviyesinden 125% seviyesine düştü.

Borç Kapsamı: GRF 'nin borcu işletme nakit akışı ( 3.6% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: GRF 'in borcuna ilişkin faiz ödemeleri EBIT ( 1.8 x kapsam) tarafından iyi karşılanmıyor.

Grifols Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Is Grifols (BME:GRF) A Risky Investment?

Recent updates

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings: EPS misses analyst expectations

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Investor sentiment deteriorates as stock falls 16%

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

New minor risk - Earnings quality

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

First quarter 2024 earnings released

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Consensus EPS estimates fall by 28%

Is Grifols (BME:GRF) A Risky Investment?

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin